FIELD: medicine.
SUBSTANCE: group of inventions relates to inhibition of an increase in an intra-neural calcium concentration. The use of an agent for inhibition of an increase in an intra-neural calcium concentration is disclosed, where the agent includes a cyclic amine derivative of the formula (I) or its pharmaceutically acceptable salt, where A is a group of the formula (IIa), (IIb), or (IIc):
,,
where R1 is a hydroxyl group or a hydrogen atom, R2 is a methyl group, an ethyl group, n-propyl group, an isopropyl group, n-butyl group, a difluoromethyl group, or 2,2,2-trifluoroethyl group, R3 is a hydrogen atom, a fluorine atom, a bromine atom, or a chlorine atom, each R4 is independently a methyl group or an ethyl group, n has a value of 1 or 2, when R1 is a hydroxyl group, carbon marked with *, an asymmetrical carbon atom. The use of a cyclic amine derivative for the treatment or prevention of a disease related to neuron hyperexcitability is also disclosed.
EFFECT: group of inventions provides expansion of the arsenal of means of a specific purpose.
21 cl, 5 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
DYNAMIC CYCLIC AMINE AND PHARMACEUTICAL APPLICATION THEREOF | 2016 |
|
RU2667062C1 |
CYCLICAMINE DERIVATIVE AS A MEANS OF STIMULATION OF THE ACTION OF ADVILLIN AND A NEW CYCLICAMINE DERIVATIVE AND ITS APPLICATION IN PHARMACEUTICALS | 2019 |
|
RU2792056C2 |
THERAPEUTIC OR PREVENTIVE MEDICINE AGAINST PERIPHERAL NEUROPATHIES | 2018 |
|
RU2770307C2 |
PYRIDINE DERIVATIVE | 2013 |
|
RU2640588C2 |
UREA DERIVATIVE | 2017 |
|
RU2768587C2 |
DERIVATIVE CYCLIC AMINE AND ITS PHARMACEUTICAL APPLICATION | 2014 |
|
RU2638549C2 |
NOVEL DERIVATIVES OF ASPARTYL DIPEPTIDE ESTER AND SWEETENING AGENTS | 1999 |
|
RU2192430C2 |
ESTER DERIVATIVES OF ASPARTYLDIPEPTIDES AND SWEETENING SUBSTANCES | 1999 |
|
RU2179979C1 |
1-IMIDAZOLE DERIVATIVES AS MODULATORS OF CANNABINOID RECEPTORS | 2004 |
|
RU2337907C2 |
THERAPEUTIC REMEDY OR PREVENTIVE REMEDY AGAINST ALOPECIA AREATA | 2018 |
|
RU2772507C2 |
Authors
Dates
2022-11-10—Published
2019-03-29—Filed